AVRO:NSD-AVROBIO, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 14.39

Change

0.00 (0.00)%

Market Cap

USD 0.60B

Volume

0.74M

Average Target Price

USD 35.00 (+143.22%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company has a research and clinical collaboration agreement with Magenta Therapeutics to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. AVROBIO, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Company Website : http://www.avrobio.com

Address : Building 300, Cambridge, MA, United States, 02139

Employees : 123

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.41

52 Week High : 29.32

Short Ratio : 9.42

52 Week Low : 9.76

Shorted Shares : 3,546,679

200 Day Moving Average : 15.70

Shorted Shares Previous Month : 2,846,538

50 Day Moving Average : 14.23

Shares Held By Insiders : 24.01%

Short Percentage : 9.00%

Shares Held by Institutions : 92.09%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD58.65B 22.10 18.26
REGN Regeneron Pharmaceuticals, Inc

N/A

 USD55.27B 18.98 14.64
MRNA Moderna, Inc

N/A

 USD51.30B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD34.27B 36.37 33.83
SGEN Seagen Inc

N/A

 USD33.25B 70.15 70.76
RPRX Royalty Pharma plc

N/A

 USD32.48B 22.60 11.90
BGNE BeiGene, Ltd

N/A

 USD31.01B N/A N/A
GMAB Genmab A/S

N/A

 USD28.77B 26.59 3.08
BNTX BioNTech SE

N/A

 USD24.46B -99,999.99 N/A
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing AVRO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.23% 28% F 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.23% 28% F 42% F
Trailing 12 Months  
Capital Gain -36.83% 18% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.83% 18% F 8% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -6.84% 32% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.84% 32% F 19% F
Risk Return Profile  
Volatility (Standard Deviation) 28.51% 84% B 51% F
Risk Adjusted Return -24.00% 28% F 22% F
Market Capitalization 0.60B 64% D 55% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.14 67% D+ 46% F
Price / Cash Flow Ratio -8.81 53% F 76% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -55.11% 58% F 20% F
Return on Invested Capital -49.20% 62% D- 19% F
Return on Assets -32.08% 40% F 11% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 9.42 14% F 9% F
Short Percent 9.85% 34% F 22% F
Beta 1.41 56% F 35% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector